Cargando…

In Situ Cocktail Nanovaccine for Cancer Immunotherapy

In situ vaccination is a desirable strategy for cancer immunotherapy due to its convenience and capacity to target tumor antigens. Here, an in situ nanovaccine based on a cationic peptide with cholesterol‐modified, DP7‐C, for cancer immunotherapy is rationally designed, and developed a cancer nanova...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Mohan, Xie, Daoyuan, Hu, Die, Zhang, Rui, Wang, Yusi, Tang, Lin, Zhou, Bailing, Zhao, Binyan, Yang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625102/ https://www.ncbi.nlm.nih.gov/pubmed/37740439 http://dx.doi.org/10.1002/advs.202207697

Ejemplares similares

A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy
por: Zhang, Rui, et al.
Publicado: (2023)

Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
por: Xie, Daoyuan, et al.
Publicado: (2023)

A Magnetic Nanovaccine Enhances Cancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2019)

A STING-Activating Nanovaccine for Cancer Immunotherapy
por: Luo, Min, et al.
Publicado: (2017)

CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021)

Artificially cloaked viral nanovaccine for cancer immunotherapy
por: Fusciello, Manlio, et al.
Publicado: (2019)

Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review
por: Fang, Xingliang, et al.
Publicado: (2022)

Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo
por: Zhao, Binyan, et al.
Publicado: (2021)

Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Sustained and targeted delivery of siRNA/DP7‐C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy
por: Zhao, Binyan, et al.
Publicado: (2021)

Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy
por: Cai, Ting, et al.
Publicado: (2021)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
por: Dong, Ying, et al.
Publicado: (2020)

Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Probiotics formulation and cancer nanovaccines show synergistic effect in immunotherapy and prevention of colon cancer
por: Xu, Xiangxiang, et al.
Publicado: (2023)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect
por: Cheng, Furong, et al.
Publicado: (2023)

Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Self-adjuvanting cancer nanovaccines
por: Liao, Zhiyun, et al.
Publicado: (2022)

Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy
por: Xie, Xiaoxue, et al.
Publicado: (2022)

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
por: Ni, Qianqian, et al.
Publicado: (2020)

Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy
por: Zhu, Guizhi, et al.
Publicado: (2017)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
por: Chen, Jie, et al.
Publicado: (2021)

Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Publicado: (2022)

STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy
por: Zhou, Lei, et al.
Publicado: (2023)

Pulmonary delivery of mucosal nanovaccines
por: Tang, Wei, et al.
Publicado: (2021)

Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
por: Li, Yueyi, et al.
Publicado: (2023)

Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy
por: Sui, Yang, et al.
Publicado: (2022)

Membrane-based cancer nanovaccines: the time is now
por: Zhao, G, et al.
Publicado: (2023)

Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy
por: He, Ao, et al.
Publicado: (2023)

Fabrication of subunit nanovaccines by physical interaction
por: Chen, HaoLin, et al.
Publicado: (2022)

Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy
por: Wang, Kaiyuan, et al.
Publicado: (2023)

Cholesterol modified DP7 and pantothenic acid induce dendritic cell homing to enhance the efficacy of dendritic cell vaccines
por: Zhang, Rui, et al.
Publicado: (2021)

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
por: Shao, Jie, et al.
Publicado: (2022)

Bacterial outer membrane vesicle-based cancer nanovaccines
por: Gao, Xiaoyu, et al.
Publicado: (2022)

Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy
por: Makandar, Amina I., et al.
Publicado: (2022)

Advancements in prophylactic and therapeutic nanovaccines
por: Bhardwaj, Prateek, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ogke3gfurgl67metmkesopiarj